Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGI-2001 for GVHD Prevention in Haploidentical Stem Cell Transplant
NCT04473911Phase 1Completed
- Start
- Aug 2020
- Primary completion
- Oct 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGI-2001 in graft-versus-host disease (GVHD) (2 arms). Primary endpoint: Number of patients achieving successful donor engraftment at 60 days. Started Aug 2020; status: completed.
02
Drugs
RGI-2001
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04473911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04473911.